Skip Navigation



JAC Advance Access published online on August 20, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh401
© 2004 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
54/3/617    most recent
dkh401v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mushtaq, S.
Right arrow Articles by Livermore, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mushtaq, S.
Right arrow Articles by Livermore, D. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Received June 8, 2004
Accepted July 15, 2004

Original article

Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods

Shazad Mushtaq 1, Marina Warner 1, Alan P. Johnson 1 *, David M. Livermore 1*

1 Antibiotic Resistance Monitoring & Reference Laboratory, Health Protection Agency Colindale, 61 Colindale Avenue, London NW9 5HT, UK

* To whom correspondence should be addressed. E-mail: david.livermore{at}hpa.org.uk.


  Abstract

Background: Dalbavancin is a long-half-life (9-12 days) glycopeptide, now in Phase 3 development. Its pharmacokinetics may facilitate home intravenous therapy, early discharge and long prophylaxis.

Methods: Dalbavancin and comparators were tested in vitro against staphylococci and streptococci to determine (i) activity and (ii) the comparability of agar dilution MICs by the BSAC and the NCCLS methods. The test panels comprised 92-93 isolates each of Staphylococcus aureus, coagulase-negative staphylococci (CoNS) and ‘viridans’ streptococci, chosen for epidemiological diversity and to over-represent strains resistant to conventional agents, including teicoplanin.

Results: Dalbavancin MICs by the BSAC and NCCLS methods generally were identical, or else those by the BSAC method were two-fold lower. In both cases the MIC distributions of dalbavancin within species groups were unimodal, with peaks at 0.25, 0.12/0.25 and 0.12 mg/L for S. aureus, CoNS and viridans streptococci, respectively. MIC differences between the BSAC and NCCLS methods were similarly small for other glycopeptides and, generally, non-glycopeptides. Dalbavancin MICs were mostly two- to 16-fold below those of vancomycin and dalbavancin--like vancomycin--remained highly active against teicoplanin-non-susceptible staphylococci.

Conclusions: Dalbavancin has good activity versus streptococci and staphylococci, including teicoplanin-resistant strains. MICs by BSAC and NCCLS agar dilution methods were comparable to each other; slightly lower MIC values, nevertheless, have been recorded by broth microdilution.

Keywords: dalbavancin; glycopeptides; susceptibility testing.

*Present address. Communicable Disease Surveillance Centre, Health Protection Agency Colindale, London NW9 5EQ, UK.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Microbiol.Home page
T. R. Fritsche, R. P. Rennie, B. P. Goldstein, and R. N. Jones
Comparison of Dalbavancin MIC Values Determined by Etest (AB BIODISK) and Reference Dilution Methods Using Gram-Positive Organisms.
J. Clin. Microbiol., August 1, 2006; 44(8): 2988 - 2990.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.